Logo image of BMRN

BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Fundamental Analysis

NASDAQ:BMRN - Nasdaq - US09061G1013 - Common Stock - Currency: USD

59.095  -0.84 (-1.39%)

Fundamental Rating

6

Taking everything into account, BMRN scores 6 out of 10 in our fundamental rating. BMRN was compared to 561 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making BMRN a very profitable company, without any liquidiy or solvency issues. A decent growth rate in combination with a cheap valuation! Better keep an eye on BMRN. These ratings would make BMRN suitable for value and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year BMRN was profitable.
BMRN had a positive operating cash flow in the past year.
BMRN had positive earnings in 4 of the past 5 years.
In the past 5 years BMRN always reported a positive cash flow from operatings.
BMRN Yearly Net Income VS EBIT VS OCF VS FCFBMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

1.2 Ratios

BMRN's Return On Assets of 7.33% is amongst the best of the industry. BMRN outperforms 93.76% of its industry peers.
With an excellent Return On Equity value of 9.04%, BMRN belongs to the best of the industry, outperforming 93.76% of the companies in the same industry.
With an excellent Return On Invested Capital value of 9.16%, BMRN belongs to the best of the industry, outperforming 94.30% of the companies in the same industry.
BMRN had an Average Return On Invested Capital over the past 3 years of 3.73%. This is significantly below the industry average of 15.87%.
The last Return On Invested Capital (9.16%) for BMRN is above the 3 year average (3.73%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.33%
ROE 9.04%
ROIC 9.16%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
BMRN Yearly ROA, ROE, ROICBMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

Looking at the Profit Margin, with a value of 17.76%, BMRN belongs to the top of the industry, outperforming 95.37% of the companies in the same industry.
The Operating Margin of BMRN (24.13%) is better than 95.90% of its industry peers.
The Gross Margin of BMRN (79.44%) is better than 84.67% of its industry peers.
BMRN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 24.13%
PM (TTM) 17.76%
GM 79.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
BMRN Yearly Profit, Operating, Gross MarginsBMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BMRN is destroying value.
BMRN has more shares outstanding than it did 1 year ago.
BMRN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BMRN has been reduced compared to a year ago.
BMRN Yearly Shares OutstandingBMRN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
BMRN Yearly Total Debt VS Total AssetsBMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

An Altman-Z score of 6.31 indicates that BMRN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.31, BMRN belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
BMRN has a debt to FCF ratio of 0.96. This is a very positive value and a sign of high solvency as it would only need 0.96 years to pay back of all of its debts.
The Debt to FCF ratio of BMRN (0.96) is better than 95.19% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
BMRN's Debt to Equity ratio of 0.10 is on the low side compared to the rest of the industry. BMRN is outperformed by 65.42% of its industry peers.
Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.96
Altman-Z 6.31
ROIC/WACC0.95
WACC9.61%
BMRN Yearly LT Debt VS Equity VS FCFBMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

BMRN has a Current Ratio of 5.52. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
BMRN has a Current ratio of 5.52. This is in the better half of the industry: BMRN outperforms 60.07% of its industry peers.
A Quick Ratio of 3.49 indicates that BMRN has no problem at all paying its short term obligations.
BMRN has a Quick ratio (3.49) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.52
Quick Ratio 3.49
BMRN Yearly Current Assets VS Current LiabilitesBMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 136.84% over the past year.
BMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.36%.
The Revenue has been growing by 10.86% on average over the past years. This is quite good.
EPS 1Y (TTM)136.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.52%
Revenue 1Y (TTM)19.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%14.84%

3.2 Future

Based on estimates for the next years, BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 27.94% on average per year.
Based on estimates for the next years, BMRN will show a small growth in Revenue. The Revenue will grow by 7.79% on average per year.
EPS Next Y56.4%
EPS Next 2Y41.9%
EPS Next 3Y33%
EPS Next 5Y27.94%
Revenue Next Year11.4%
Revenue Next 2Y10.74%
Revenue Next 3Y9.65%
Revenue Next 5Y7.79%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BMRN Yearly Revenue VS EstimatesBMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
BMRN Yearly EPS VS EstimatesBMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 21.89 indicates a rather expensive valuation of BMRN.
BMRN's Price/Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 95.01% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.60. BMRN is around the same levels.
With a Price/Forward Earnings ratio of 13.28, BMRN is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 94.83% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of BMRN to the average of the S&P500 Index (22.43), we can say BMRN is valued slightly cheaper.
Industry RankSector Rank
PE 21.89
Fwd PE 13.28
BMRN Price Earnings VS Forward Price EarningsBMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

BMRN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BMRN is cheaper than 95.72% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BMRN is valued cheaply inside the industry as 95.54% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 18.27
EV/EBITDA 13.19
BMRN Per share dataBMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BMRN has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 33.00% in the coming years.
PEG (NY)0.39
PEG (5Y)N/A
EPS Next 2Y41.9%
EPS Next 3Y33%

More info and screens

0

5. Dividend

5.1 Amount

BMRN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOMARIN PHARMACEUTICAL INC

NASDAQ:BMRN (5/21/2025, 11:08:51 AM)

59.095

-0.84 (-1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners98.66%
Inst Owner Change0.99%
Ins Owners0.69%
Ins Owner Change7.05%
Market Cap11.33B
Analysts82.86
Price Target97.98 (65.8%)
Short Float %2.37%
Short Ratio2.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.95%
Min EPS beat(2)18.43%
Max EPS beat(2)31.48%
EPS beat(4)4
Avg EPS beat(4)27.84%
Min EPS beat(4)4.22%
Max EPS beat(4)57.23%
EPS beat(8)6
Avg EPS beat(8)15.96%
EPS beat(12)9
Avg EPS beat(12)-4.68%
EPS beat(16)13
Avg EPS beat(16)7.99%
Revenue beat(2)1
Avg Revenue beat(2)0.66%
Min Revenue beat(2)-1.37%
Max Revenue beat(2)2.69%
Revenue beat(4)3
Avg Revenue beat(4)2.79%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)5.44%
Revenue beat(8)3
Avg Revenue beat(8)-0.01%
Revenue beat(12)5
Avg Revenue beat(12)-0.3%
Revenue beat(16)7
Avg Revenue beat(16)-0.11%
PT rev (1m)-0.83%
PT rev (3m)-0.94%
EPS NQ rev (1m)8.96%
EPS NQ rev (3m)20.77%
EPS NY rev (1m)5.89%
EPS NY rev (3m)11.64%
Revenue NQ rev (1m)-0.89%
Revenue NQ rev (3m)0.47%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)1.17%
Valuation
Industry RankSector Rank
PE 21.89
Fwd PE 13.28
P/S 3.84
P/FCF 18.27
P/OCF 16.18
P/B 1.96
P/tB 2.12
EV/EBITDA 13.19
EPS(TTM)2.7
EY4.57%
EPS(NY)4.45
Fwd EY7.53%
FCF(TTM)3.23
FCFY5.47%
OCF(TTM)3.65
OCFY6.18%
SpS15.39
BVpS30.21
TBVpS27.9
PEG (NY)0.39
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.33%
ROE 9.04%
ROCE 10.92%
ROIC 9.16%
ROICexc 11.38%
ROICexgc 12.43%
OM 24.13%
PM (TTM) 17.76%
GM 79.44%
FCFM 21.02%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.96
Debt/EBITDA 0.74
Cap/Depr 87.86%
Cap/Sales 2.71%
Interest Coverage 79.64
Cash Conversion 87.19%
Profit Quality 118.38%
Current Ratio 5.52
Quick Ratio 3.49
Altman-Z 6.31
F-Score8
WACC9.61%
ROIC/WACC0.95
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)136.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.52%
EPS Next Y56.4%
EPS Next 2Y41.9%
EPS Next 3Y33%
EPS Next 5Y27.94%
Revenue 1Y (TTM)19.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%14.84%
Revenue Next Year11.4%
Revenue Next 2Y10.74%
Revenue Next 3Y9.65%
Revenue Next 5Y7.79%
EBIT growth 1Y301.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year84.98%
EBIT Next 3Y19.03%
EBIT Next 5Y23.16%
FCF growth 1Y2744.87%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y375.08%
OCF growth 3Y23.45%
OCF growth 5Y63.99%